← back to search

Shu Li

Johnson & Johnson (United States) · US
Area of research
Immunology · Rheumatology
Research interest
Research interests include Psoriasis: Treatment and Pathogenesis, Spondyloarthritis Studies and Treatments, Dermatology and Skin Diseases, and Rheumatoid Arthritis Research and Therapies.
h-index
31
citations
12,206
works
58
NIH funding
primary concept
email

Recent publications

Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
The Lancet 2025cited by 12position: middledoi
Etanercept ameliorates psoriasis progression through regulating high mobility group box 1 pathway
Skin Research and Technology 2023cited by 8position: firstdoi
Gut microbiota from patients with arteriosclerotic CSVD induces higher IL-17A production in neutrophils via activating RORγt
Science Advances 2021cited by 43position: middledoi
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Journal of the American Academy of Dermatology 2017cited by 852position: middledoi
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
Journal of the American Academy of Dermatology 2017cited by 724position: middledoi
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
New England Journal of Medicine 2015cited by 293position: middledoi
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
Journal of the American Academy of Dermatology 2015cited by 223position: middledoi
Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial
Arthritis Care & Research 2015cited by 105position: middledoi
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Annals of the Rheumatic Diseases 2014cited by 657position: middledoi
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
The Lancet 2013cited by 795position: middledoi

Grants

I-Corps: Cloud-based Water Resources Simulations
NSF1340974$50,0002013–2013PIRePORTER
A Hierarchical and Patch Dynamics Paradigm for Modeling Complex, 3D Groundwater Systems Across Multiple Scales
NSF0523107$124,9302005–2009PIRePORTER
SEI+II (GEO): An IT-Enabled, Hierarchical and Patch Dynamic Environment for Modeling Complex, 3D Groundwater Systems Across Multiple Spatial Scales
NSF0430987$550,0002004–2008PIRePORTER
VIRGE: Virtual Interactive Remediation in the Groundwater Environment - An Action Oriented Curriculum Innovation in Environmental Engineering
NSF0088137$394,4052001–2002PIRePORTER
VIRGE: Virtual Interactive Remediation in the Groundwater Environment - An Action Oriented Curriculum Innovation in Environmental Engineering
NSF0296199$343,0492001–2004PIRePORTER
Stochastic Flow and Transport in Heterogeneous Soils: Nonstationarity, Scale Interaction, and an Efficient Modeling Framework
NSF0296072$84,5762001–2002PIRePORTER
Stochastic Flow and Transport in Heterogeneous Soils: Nonstationarity, Scale Interaction, and an Efficient Modeling Framework
NSF9811895$192,6681999–2001PIRePORTER
Stochastic Flow and Transport in Heterogeneous Soils: A New Approach for Measurement Conditioning
NSF9805357$97,3631998–2000PIRePORTER
Reductive Dual Pairs in Exceptional Groups: Cohomology, and Unipotent Representations
NSF9801713$70,5961998–2001PIRePORTER
Mathematical Sciences: Singular Unitary Representations and Cohomology of Arithmetic Manifolds
NSF9501092$75,0001995–1998PIRePORTER
Mathematical Sciences: Discrete Spectrum of the Oscillator Representation and Applications
NSF9206393$63,2251992–1996PIRePORTER
Mathematical Sciences: Theta Lifting and Cohomology of Discrete Subgroups
NSF9003999$35,1001990–1992PIRePORTER

Frequent collaborators

B. Randazzo · AnaBios (United States)4 papers (2015–2017) · 4 papers (2014–2017)Arthur Kavanaugh · UC San Diego Health System3 papers (2013–2015) · 3 papers (2013–2015) · 3 papers (2015–2017)Christopher T. Ritchlin · University of Alabama at Birmingham3 papers (2013–2015) · 3 papers (2013–2015)Alice B. Gottlieb · Yale University3 papers (2013–2015)Proton Rahman · Memorial University of Newfoundland3 papers (2013–2015)Iain B. McInnes · University of Glasgow3 papers (2013–2015) · 2 papers (2015–2015)Kristian Reich · Universität Hamburg2 papers (2015–2017) · 2 papers (2015–2015)Kenneth B. Gordon · Medical College of Wisconsin2 papers (2015–2017) · 2 papers (2015–2017)Mittie K. Doyle · California University of Pennsylvania2 papers (2013–2014)Yuhua Wang · Tianjin University of Traditional Chinese Medicine2 papers (2013–2015)Jörg C. Prinz · Ludwig-Maximilians-Universität München1 papers (2015–2015)Ling Li · Royal Berkshire NHS Foundation Trust1 papers (2023–2023)Xiaoyan Li · The First Affiliated Hospital, Sun Yat-sen University1 papers (2023–2023)